MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program

First patient was administered today

The trial aims at validating the safety of continuous administration of Ivermectin in oral form

Simultaneously, several long-acting injectable formulations based on MedinCell's BEPO^® technology are being tested in vivo

A 1-month active injectable prophylactic treatment should be ready to enter regulatory development before the end of the year

MedinCell may file for market authorization as early as 2021

Universal vaccination remains very hypothetical; this preventive treatment should be essential in all scenarios

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL):

Access the complete press release

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO^® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO^® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.